ALRN - the clinical-stage leader in the field of stabilized & cell-permeating peptides.
2020 Catalysts
ALRN-6924 and IBRANCE (palbociclib) - Phase 2a final data due 2Q 2020 - IBRANCE (Developed & owned by Pfizer)
Solid tumors
-----------------------------------------------------------------------------------------
ALRN-6924 - Phase 1b/2 dose-optimization data due 2Q 2020
Small Cell Lung Cancer
-----------------------------------------------------------------------------------------
Cash Position:
Cash equivalents and investments as of September 30, 2019 were $24.6 million, compared to $20.7 million as of December 31, 2018. The Company believes that its cash, cash equivalents and investments as of September 30, 2019 will be sufficient to fund its operations and capital expenditure requirements into the fourth quarter of 2020.
2020 Catalysts
ALRN-6924 and IBRANCE (palbociclib) - Phase 2a final data due 2Q 2020 - IBRANCE (Developed & owned by Pfizer)
Solid tumors
-----------------------------------------------------------------------------------------
ALRN-6924 - Phase 1b/2 dose-optimization data due 2Q 2020
Small Cell Lung Cancer
-----------------------------------------------------------------------------------------
Cash Position:
Cash equivalents and investments as of September 30, 2019 were $24.6 million, compared to $20.7 million as of December 31, 2018. The Company believes that its cash, cash equivalents and investments as of September 30, 2019 will be sufficient to fund its operations and capital expenditure requirements into the fourth quarter of 2020.